In this free webinar, learn about incretins and their effects throughout the body. Attendees will learn why the future of incretin drug development will likely expand with different combinations, formulations and disease indications. The featured speakers will discuss how advanced imaging techniques like magnetic resonance imaging and positron emission tomography can help us better understand incretins and their effects.
TORONTO , April 16, 2024 /PRNewswire-PRWeb/ -- With the demonstrated efficacy and approvals of recent incretin-based therapies for the treatment of diabetes and obesity, one might think this is it for incretins. But really, it is just the beginning — given the possibilities for new combinations, different formulations and more indications throughout metabolic diseases and beyond.
What are incretins and how do they really work? How can we better understand their effects and advance drug development in obesity and metabolic disease? What will the future of incretin-based drug development look like?
It is currently a very exciting time within drug development for incretins, but there is still a lot we do not know. In this webinar, the expert speakers will cover how incretins were discovered, what we know about them, current challenges facing incretin drug development and some of the exciting work that is ongoing in this space. They will also discuss how advanced imaging techniques like magnetic resonance imaging (MRI) and positron emission tomography (PET) can give us insights that will help us to better understand incretins, as well as provide relevant information for future drug development.
Register for this webinar today to learn about incretins, the current status of incretin drug development and the speakers' perspectives on the future of incretin drug development.
Join Tina Vilsbøll, MD, DMSc, Professor at Steno Diabetes Centre Copenhagen, University of Copenhagen, Denmark; Michael Wagner, Senior Vice President, Chemistry and Drug Discovery, Dewpoint Therapeutics; Co-Founder, Antaros Tracer; and Martin Schain, Director of PET Imaging, Antaros Medical, for the live webinar on Thursday, May 2, 2024, at 11am EDT (4pm BST/UK).
For more information, or to register for this event, visit The Incretin Impact: A New Era in Metabolic Disease and Obesity Drug Development.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected], https://xtalks.com
SOURCE Xtalks
Share this article